Dalbavancin (PDF Version)
Glycopeptide
Staphylococcus aureus (Oritavancin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Oritavancin susceptible), C. jeikeium, Clostridium spp. (except clostridioforme),, Actinomyces, Propionibacterium spp.,
Oritavancin inhibits the bacterial cell wall biosynthesis by binding to the C-terminal of the D-alanyl-D-alanine peptidoglycan chain
Pharmacodynamics:
No data
Phase III studies ongoing
Studies ongoing
Dosage:
Not commercially available
Disease state based dosing:
Not yet determined
Contraindications/Warnings/Precautions:
Not yet determined
Drug Interactions:
Unknown
Pregnancy:
Unknown
Monitoring Requirements:
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Brand names/Manufacturer: Not currently available